Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT
Targeting EndMT based on the SIRT1/Notch1 pathway, BHYF may represent a novel antifibrotic therapeutic strategy, providing a scientific basis for the development of new cardiovascular drugs.
Authors
- Chengzhi Hou (ORCID: https://orcid.org/0009-0007-3842-1934)
- Wenjing Lian
- Jun Hu (ORCID: https://orcid.org/0000-0002-7569-3433)
- Cong Chen (ORCID: https://orcid.org/0000-0002-8111-8718)
- Jie Wang (ORCID: https://orcid.org/0000-0001-7870-0646)
- Chao Liu (ORCID: https://orcid.org/0000-0003-1806-9930)
- Xueying Zhu (ORCID: https://orcid.org/0000-0003-1522-4587)
Institutions
- Beijing University of Chinese Medicine (CN)
- Guang’anmen Hospital (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1016/j.phymed.2024.156252
- Citations
- 8
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 3.22